ArQule Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
74,695.00
59,208.00
38,772.00
31,126.00
48,036.00
99,558
Other Current Assets
941.00
1,893.00
714.00
822.00
547.00
861
Total Current Assets
75,636.00
61,101.00
39,486.00
31,948.00
48,583.00
106,403
Net Property, Plant & Equipment
1,128.00
133.00
266.00
180.00
115.00
69
Total Investments and Advances
20,391.00
2,058.00
-
-
-
-
Other Assets
1,024.00
102.00
252.00
252.00
204.00
204
Total Assets
98,179.00
63,394.00
40,004.00
32,380.00
48,902.00
106,676
ST Debt & Current Portion LT Debt
1,700.00
-
-
-
-
Accounts Payable
146.00
259.00
186.00
710.00
537.00
Other Current Liabilities
19,907.00
18,018.00
10,639.00
7,990.00
9,222.00
Total Current Liabilities
21,753.00
18,277.00
10,825.00
8,700.00
9,759.00
Long-Term Debt
-
-
-
-
14,607.00
Other Liabilities
15,800.00
4,572.00
-
-
1,512.00
Total Liabilities
37,553.00
22,849.00
10,825.00
8,700.00
25,878.00
Common Equity (Total)
60,626.00
40,545.00
29,179.00
23,680.00
14,181.00
Total Shareholders' Equity
60,626.00
40,545.00
29,179.00
23,680.00
23,024.00
Total Equity
60,626.00
40,545.00
29,179.00
23,680.00
23,024.00
Liabilities & Shareholders' Equity
98,179.00
63,394.00
40,004.00
32,380.00
48,902.00
Preferred Stock (Carrying Value)
-
-
-
-
8,843.00

About ArQule

View Profile
Address
One Wall Street
Burlington Massachusetts 01803
United States
Employees -
Website http://www.arqule.com
Updated 07/08/2019
ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761.